Elevated plasma homocysteine in early pregnancy: A risk factor for the development of severe preeclampsia

被引:111
作者
Cotter, AM [1 ]
Molloy, AM
Scott, JM
Daly, SF
机构
[1] Coombe Womens Hosp, Dublin 8, Ireland
[2] Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland
关键词
homocysteine; preeclampsia; folate; vitamin B-12; methylenetetrahydrofolate reductase polymorphism;
D O I
10.1067/mob.2001.117304
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: The aim of our study was to determine if an elevated plasma homocysteine level In early pregnancy is associated with the development of severe preeclampsia. STUDY DESIGN: Blood samples were obtained from patients attending their first antenatal visit. Cases were asymptomatic women who subsequently developed severe preeclampsia. Controls were matched for gestational age and date of sample collection. Plasma homocysteine level was measured by using fluorescence polarization immunoassay. RESULTS: There were 56 patients with severe preeclampsia from whom blood samples were obtained at a mean (+/- SD) gestation of 15.3 weeks (+/-4.04 weeks) and 112 controls at 14.9 weeks (+/-3.41 weeks). The preeclampsia cases had a mean (+/- SD) homocysteine level of 9.8 mu mol/L (+/-3.3 mu mol/L), whereas controls had a mean homocysteine level of 8.4 mu mol/L (+/-1.9 mu mol/L), P less than or equal to .0001. CONCLUSION: Women who develop severe preeclampsia have higher plasma homocysteine levels in early pregnancy than women who remain normotensive throughout pregnancy. An elevated plasma homocysteine level In early pregnancy can increase the risk of developing severe preeclampsia by almost threefold.
引用
收藏
页码:781 / 785
页数:5
相关论文
共 19 条
[1]   A QUANTITATIVE ASSESSMENT OF PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR VASCULAR-DISEASE - PROBABLE BENEFITS OF INCREASING FOLIC-ACID INTAKES [J].
BOUSHEY, CJ ;
BERESFORD, SAA ;
OMENN, GS ;
MOTULSKY, AG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (13) :1049-1057
[2]   FOLATE LEVELS AND NEURAL-TUBE DEFECTS - IMPLICATIONS FOR PREVENTION [J].
DALY, LE ;
KIRKE, PN ;
MOLLOY, A ;
WEIR, DG ;
SCOTT, JM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (21) :1698-1702
[3]   UNDERLYING DISORDERS ASSOCIATED WITH SEVERE EARLY-ONSET PREECLAMPSIA [J].
DEKKER, GA ;
DEVRIES, JIP ;
DOELITZSCH, PM ;
HUIJGENS, PC ;
VONBLOMBERG, BME ;
JAKOBS, C ;
VANGEIJN, HP .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1995, 173 (04) :1042-1048
[4]   A CANDIDATE GENETIC RISK FACTOR FOR VASCULAR-DISEASE - A COMMON MUTATION IN METHYLENETETRAHYDROFOLATE REDUCTASE [J].
FROSST, P ;
BLOM, HJ ;
MILOS, R ;
GOYETTE, P ;
SHEPPARD, CA ;
MATTHEWS, RG ;
BOERS, GJH ;
DENHEIJER, M ;
KLUIJTMANS, LAJ ;
VANDENHEUVEL, LP ;
ROZEN, R .
NATURE GENETICS, 1995, 10 (01) :111-113
[5]  
Grandone E, 1997, THROMB HAEMOSTASIS, V77, P1052
[6]   MICROBIOLOGICAL ASSAY FOR VITAMIN-B-12 PERFORMED IN 96-WELL MICROTITRE PLATES [J].
KELLEHER, BP ;
BROIN, SDO .
JOURNAL OF CLINICAL PATHOLOGY, 1991, 44 (07) :592-595
[7]  
KIRKE PN, 1993, Q J MED, V86, P703
[8]  
Leino A, 1999, CLIN CHEM, V45, P569
[9]  
Molloy AM, 1997, METHOD ENZYMOL, V281, P43
[10]   Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: Implications for folate intake recommendations [J].
Molloy, AM ;
Daly, S ;
Mills, JL ;
Kirke, PN ;
Whitehead, AS ;
Ramsbottom, D ;
Conley, MR ;
Weir, DG ;
Scott, JM .
LANCET, 1997, 349 (9065) :1591-1593